BridgeBio Pharma, Inc.

Contributing Author

Recent Articles by BridgeBio Pharma, Inc.

15 hours	BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 BBIO GlobeNewswire
Oct-29	BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates BBIO GlobeNewswire
Oct-29	BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 BBIO GlobeNewswire
Oct-28	BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th BBIO GlobeNewswire
Oct-27	BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study BBIO GlobeNewswire
Oct-24	BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week BBIO GlobeNewswire
Oct-03	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBIO GlobeNewswire
Sep-28	Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM BBIO GlobeNewswire
Sep-22	BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 BBIO GlobeNewswire
Sep-10	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBIO GlobeNewswire
Sep-06	Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism BBIO GlobeNewswire
Sep-03	BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET BBIO GlobeNewswire
Sep-02	BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism BBIO GlobeNewswire
Aug-30	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension BBIO GlobeNewswire
Aug-27	BridgeBio to Participate in September Investor Conferences BBIO GlobeNewswire
Aug-25	BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 BBIO GlobeNewswire
Aug-05	BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates BBIO GlobeNewswire
Jul-23	Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 BBIO GlobeNewswire
Jul-22	BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET BBIO GlobeNewswire
Jun-30	BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty BBIO GlobeNewswire
Jun-26	BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET BBIO GlobeNewswire
Jun-02	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 BBIO GlobeNewswire
May-20	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM BBIO GlobeNewswire
May-19	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study BBIO GlobeNewswire
May-14	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BBIO GlobeNewswire
May-13	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study BBIO GlobeNewswire
May-12	BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC BBIO GlobeNewswire
May-07	BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 BBIO GlobeNewswire

BridgeBio Pharma, Inc.

Recent Articles by BridgeBio Pharma, Inc.

Upgrade your FINVIZ experience